10
results
for author:"DeFazio A."
in Literature Citations
| Mutation of FOXL2 in granulosa-cell tumors of the ovary. Shah S.P., Kobel M., Senz J., Morin R.D., Clarke B.A., Wiegand K.C., Leung G., Zayed A., Mehl E., Kalloger S.E. et al. N. Engl. J. Med. 360:2719-2729(2009) · Mapped (6) |
| Polymorphisms in the FGF2 gene and risk of serous ovarian cancer: results from the ovarian cancer association consortium. Johnatty S.E., Beesley J., Chen X., Spurdle A.B., Defazio A., Webb P.M., Goode E.L., Rider D.N., Vierkant R.A., Anderson S. et al. Twin Res Hum Genet 12:269-275(2009) · Mapped (1) |
| Mutation of ERBB2 provides a novel alternative mechanism for the ubiquitous activation of RAS-MAPK in ovarian serous low malignant potential tumors. Anglesio M.S., Arnold J.M., George J., Tinker A.V., Tothill R., Waddell N., Simms L., Locandro B., Fereday S., Traficante N. et al. Mol. Cancer Res. 6:1678-1690(2008) · Mapped (8) |
| Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer. Scurr L.L., Guminski A.D., Chiew Y.E., Balleine R.L., Sharma R., Lei Y., Pryor K., Wain G.V., Brand A., Byth K. et al. Clin. Cancer Res. 14:6924-6932(2008) · Mapped (3) |
| ABCB1 (MDR 1) polymorphisms and progression-free survival among women with ovarian cancer following paclitaxel/carboplatin chemotherapy. Johnatty S.E., Beesley J., Paul J., Fereday S., Spurdle A.B., Webb P.M., Byth K., Marsh S., McLeod H., Harnett P.R. et al. Clin. Cancer Res. 14:5594-5601(2008) · Mapped (8) |
| The E3 ubiquitin ligase EDD is an adverse prognostic factor for serous epithelial ovarian cancer and modulates cisplatin resistance in vitro. O'Brien P.M., Davies M.J., Scurry J.P., Smith A.N., Barton C.A., Henderson M.J., Saunders D.N., Gloss B.S., Patterson K.I., Clancy J.L. et al. Br. J. Cancer 98:1085-1093(2008) · Mapped (3) |
| Patterns of somatic mutation in human cancer genomes. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., Davies H., Teague J., Butler A., Stevens C. et al. Nature 446:153-158(2007) · UniProtKB (453) |
| Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer. Byrne J.A., Balleine R.L., Schoenberg Fejzo M., Mercieca J., Chiew Y.E., Livnat Y., St Heaps L., Peters G.B., Byth K., Karlan B.Y. et al. Int. J. Cancer 117:1049-1054(2005) · Mapped (3) |
| Expression of progesterone receptors A and B in the mouse ovary during the estrous cycle. Gava N., Clarke C.L., Byth K., Arnett-Mansfield R.L., deFazio A. Endocrinology 145:3487-3494(2004) · Mapped (6) |
| Subnuclear distribution of progesterone receptors A and B in normal and malignant endometrium. Arnett-Mansfield R.L., DeFazio A., Mote P.A., Clarke C.L. J. Clin. Endocrinol. Metab. 89:1429-1442(2004) · Mapped (10) |
